Qubit Pharmaceuticals in the news

Qubit Pharmaceuticals achieved theoretical and practical quantum computing breakthroughs that accelerate drug discovery simulations, aiming for commercial utility by 2028.

Qubit Pharmaceuticals was named a 2025 laureate of La French Tech 2030 for its pioneering work in AI and quantum-accelerated molecular simulation.

AI and quantum computing are accelerating drug discovery by enabling faster, cheaper virtual testing of candidate molecules, as demonstrated by Qubit Pharmaceuticals.

FeNNix-Bio1 is a fast, quantum-accurate AI model for molecular simulation that accelerates drug discovery by enabling large-scale, precise virtual screening of compounds.

Qubit Pharmaceuticals and Sorbonne University developed FeNNix-Bio1, a fast, precise AI model simulating molecular dynamics to accelerate drug discovery and other molecular design tasks.

Qubit Pharmaceuticals and Sorbonne University introduced Fennix-Bio1, an AI-powered molecular modeling tool that significantly speeds up and reduces costs in preclinical drug development by simulating molecular interactions with high precision.

Qubit Pharmaceuticals accelerates drug discovery using quantum simulations and AI, focusing on cancer and inflammatory diseases, and plans to license validated drug candidates to pharma companies.

Qubit Pharmaceuticals launched a Quantum AI model to improve drug discovery using quantum physics.

Romain Delassus joins Qubit Pharmaceuticals to lead product and tech development, supporting their advanced AI and quantum computing drug discovery platform.

Qubit Pharmaceuticals created FeNNix-Bio1, a fast, precise AI model that simulates molecular dynamics and interactions using synthetic quantum data, advancing drug discovery and chemistry.

Qubit Pharmaceuticals introduced FeNNix-Bio1, a quantum AI platform that accelerates drug discovery by precisely simulating molecular interactions and reactivity, reducing costs and time.

Qubit Pharmaceuticals uses an advanced quantum AI model to simulate molecular interactions precisely and efficiently, accelerating drug discovery and surpassing existing AI methods.

Qubit Pharmaceuticals developed Fennix-Bio1, an AI model that accelerates and improves molecular simulations for drug discovery by modeling dynamic protein interactions with unprecedented accuracy.

Qubit Pharmaceuticals and Sorbonne University developed Fennix-Bio1, an advanced AI model that accelerates and reduces costs in drug development by simulating molecular interactions with high precision.

Qubit Pharmaceuticals introduced FeNNix-Bio1, a quantum AI model enabling highly accurate, large-scale molecular simulations for drug discovery and biomolecular research.

Qubit Pharmaceuticals and Sorbonne University introduced FeNNix-Bio1, a highly advanced AI for precise and fast molecular simulation in drug discovery.

Qubit Pharmaceuticals and Sorbonne University introduced FeNNix-Bio1, an AI model improving molecular simulations for drug discovery.

Qubit Pharmaceuticals and Sorbonne University launched FeNNix-Bio1, a quantum AI model that accurately simulates molecular interactions to accelerate and reduce costs in drug discovery and beyond.

FeNNix-Bio1 leverages AI and quantum chemistry to accelerate and improve molecular simulations, enhancing drug discovery and materials science.

Sorbonne University’s upcoming Innovation Centre will host Qubit Pharmaceuticals, which uses quantum computing and AI to enhance drug discovery, alongside other quantum tech startups.